An Open-label, Randomized, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Daclatasvir, Asunaprevir, and BMS-791325 Following Administration of a Single Fixed Dose Combination of DCV 3DAA FDC in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2014
Price : $35 *
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 09 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov .
- 04 Apr 2014 New trial record